Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
As of early 2026, multiple Phase 3 trials have reported positive topline results, regulatory submissions have been filed, and the FDA is reviewing orforglipron for an obesity indication with a target action date of April 10, 2026
Research presented at the European Congress on Obesity (ECO) in Istanbul showed the effectiveness of daily oral orforglipron, known as Foundayo, and developed by US company Eli Lilly
177 In vivo, mitochondrial dynamics-related factor Parkin was significantly reduced in the substantia nigra of a mice fed a high-fat diet and a diabetic mice, leading to the accumulation of Parkin-interacting substrate and the reduction of PGC-1
Many patients we see for musculoskeletal, neurological, or cardiopulmonary conditions will have hypothyroidism on their problem list or levothyroxine on their medication list
US$ 21.21
US$ 24.26
US$ 27.79
US$ 28.33
US$ 20.91
US$ 24.60
US$ 24.42
US$ 23.31
US$ 26.94
